Compare GSK Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs CADILA HEALTHCARE - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA CADILA HEALTHCARE GSK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 51.3 14.5 353.6% View Chart
P/BV x 10.8 2.8 381.1% View Chart
Dividend Yield % 1.5 1.4 101.4%  

Financials

 GSK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
CADILA HEALTHCARE
Mar-18
GSK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,595558 644.3%   
Low Rs1,253362 346.6%   
Sales per share (Unadj.) Rs184.7116.3 158.8%  
Earnings per share (Unadj.) Rs26.317.9 147.2%  
Cash flow per share (Unadj.) Rs29.223.1 126.1%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.80.8 108.4%  
Book value per share (Unadj.) Rs126.385.4 147.9%  
Shares outstanding (eoy) m169.401,023.74 16.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.0 332.0%   
Avg P/E ratio x92.225.7 358.3%  
P/CF ratio (eoy) x83.119.9 418.2%  
Price / Book Value ratio x19.25.4 356.5%  
Dividend payout %76.119.6 388.3%   
Avg Mkt Cap Rs m410,626470,664 87.2%   
No. of employees `0005.011.8 42.0%   
Total wages/salary Rs m5,37218,545 29.0%   
Avg. sales/employee Rs Th6,306.710,072.7 62.6%   
Avg. wages/employee Rs Th1,083.11,569.1 69.0%   
Avg. net profit/employee Rs Th898.01,547.7 58.0%   
INCOME DATA
Net Sales Rs m31,281119,049 26.3%  
Other income Rs m1,0231,132 90.4%   
Total revenues Rs m32,304120,181 26.9%   
Gross profit Rs m6,00928,475 21.1%  
Depreciation Rs m4865,388 9.0%   
Interest Rs m6911 0.7%   
Profit before tax Rs m6,54023,308 28.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3735,644 42.0%   
Profit after tax Rs m4,45418,292 24.3%  
Gross profit margin %19.223.9 80.3%  
Effective tax rate %36.324.2 149.8%   
Net profit margin %14.215.4 92.7%  
BALANCE SHEET DATA
Current assets Rs m20,06182,005 24.5%   
Current liabilities Rs m14,54360,720 24.0%   
Net working cap to sales %17.617.9 98.7%  
Current ratio x1.41.4 102.1%  
Inventory Days Days5773 77.6%  
Debtors Days Days1498 14.3%  
Net fixed assets Rs m14,34383,703 17.1%   
Share capital Rs m1,6941,024 165.4%   
"Free" reserves Rs m19,70486,421 22.8%   
Net worth Rs m21,39887,445 24.5%   
Long term debt Rs m225,551 0.0%   
Total assets Rs m39,113180,653 21.7%  
Interest coverage x1,091.026.6 4,103.8%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.7 121.4%   
Return on assets %11.410.6 107.3%  
Return on equity %20.820.9 99.5%  
Return on capital %31.922.0 145.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53442,683 1.3%   
Fx outflow Rs m7,09111,242 63.1%   
Net fx Rs m-6,55731,441 -20.9%   
CASH FLOW
From Operations Rs m3,9949,193 43.4%  
From Investments Rs m-1,433-9,737 14.7%  
From Financial Activity Rs m-3,584515 -695.8%  
Net Cashflow Rs m-1,023-29 3,528.3%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.3 122.9%  
FIIs % 23.8 5.9 403.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 11.0 140.0%  
Shareholders   102,036 44,069 231.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS